MORRISVILLE, N.C. – January 24, 2023 – Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced that it has closed on $25 million of additional equity funding. The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap.
“Metabolon is experiencing significant growth, and we are excited to continue building our talented team and scaling our capabilities to meet increasing demand,” said Rohan (Ro) Hastie, Metabolon’s Chief Executive Officer. “Metabolomics is an essential component of the life science ecosystem. All omics approaches – genomics, proteomics, metabolomics – are highly complementary. You cannot fully understand biology, and more specifically systems biology, by just looking at DNA, proteins, or metabolites exclusively. As life sciences evolve toward a more sophisticated multi-omics approach, Metabolon is fast becoming an industry standard and a critical step toward true precision medicine.”
“This financing arrives on the heels of record revenue and margins in 2022 and comes predominantly from new investors, with additional participation by existing investors. The infusion of capital will allow us to continue accelerating our already robust growth and execution as we bring market-leading metabolomics and the associated deep phenotyping capabilities to a rapidly expanding market,” said Gerry Haines, CFO of Metabolon.